Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

The Efficacy and Toxicity of Aggressive Thoracic Radiotherapy for Stage Ⅳ Non-Small Cell Lung Cancer Patients With Controlled Extrathoracic Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03565120
• Other study ID #: ATR-NSCLC
• Status: Recruiting
• Phase: N/A
• Start date: December 10, 2018
• Est. completion date: December 2023

Study information

• Verified date: December 2018
• Source: Jiangmen Central Hospital
• Contact: Li chunming, master
• Phone: (+86)07503165905
• Email: 52212007[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies the safety and efficacy of aggressive thoracic radiotherapy in treating patients with non-small cell lung cancer that has not progressed after the first line systemic therapy. In this trial, patients with stage Ⅳ non small cell lung cancer who did not progress after first line systemic therapy will receive the aggressive thoracic radiotherapy, and the safety and efficacy of aggressive thoracic radiotherapy will be evaluated. The primary end points of the study are overall survival (OS), the secondary end points are local control rate, local progression free survival(LPFS), PFS, and toxicity and quality of life(QOL).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• histologically or cytologically confirmed NSCLC

• stage IV disease

• no progression after first line systemic therapy

• 18 to 80 years of age

• Karnofsky performance status(KPS) score =70%

• no contraindications to radiation therapy

• presumed ability to tolerate thoracic radiation therapy to a BED=53Gy

Exclusion Criteria:

• a history of thoracic surgery, radiation therapy, or more than first line chemotherapy

• pregnancy or lactation at the time of enrollment

• previous malignancy or other concomitant malignant disease

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Stage IV
• Thoracic Radiotherapy

Intervention

Radiation:
• Aggressive Thoracic Radiotherapy
The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)=53Gray(Gy)

Locations

Country	Name	City	State
China	Jiangmen central hospital	Jiangmen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
yu gengsheng

Country where clinical trial is conducted

China, 

References & Publications (9)

Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015 Dec 31;10(12):e0145936. doi: 10.1371/journal.pone.0145936. eCollection 2015. — View Citation

Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008 Aug 20;26(24):4001-11. doi: 10.1200/JCO.2007.15.3312. Review. — View Citation

Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, Kwok Y. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):19-23. doi: 10.1016/j.ijrobp.2007.12.031. Epub 2008 Feb 14. — View Citation

Kepka L, Olszyna-Serementa M. Palliative thoracic radiotherapy for lung cancer. Expert Rev Anticancer Ther. 2010 Apr;10(4):559-69. doi: 10.1586/era.10.22. Review. — View Citation

Koshy M, Malik R, Mahmood U, Rusthoven CG, Sher DJ. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. Pract Radiat Oncol. 2015 Nov-Dec;5(6):374-82. doi: 10.1016/j.prro.2015.07.009. Epub 2015 Aug 1. — View Citation

Sheu T, Heymach JV, Swisher SG, Rao G, Weinberg JS, Mehran R, McAleer MF, Liao Z, Aloia TA, Gomez DR. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):850-7. doi: 10.1016/j.ijrobp.2014.07.012. Epub 2014 Sep 9. — View Citation

Su S, Hu Y, Ouyang W, Ma Z, Li Q, Li H, Wang Y, Wang X, Li T, Li J, Chen M, Lu Y, Bai Y, He Z, Lu B. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. BMC Cancer. 2016 Nov 21;16(1):908. — View Citation

Su SF, Hu YX, Ouyang WW, Lu B, Ma Z, Li QS, Li HQ, Geng YC. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. BMC Cancer. 2013 Oct 12;13:474. doi: 10.1186/1471-2407-13-474. — View Citation

Wang J, Ji Z, Wang X, Liang J, Hui Z, Lv J, Zhou Z, Yin W, Wang L. Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer. Thorac Cancer. 2016 Mar;7(2):182-9. doi: 10.1111/1759-7714.12305. Epub 2015 Sep 13. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS	overall survival	two years after the beginning of first line systemic therapy
Secondary	LPFS	local progression free survival	1 year after the beginning of first line systemic therapy
Secondary	PFS	progression free survival	1 year after the beginning of first line systemic therapy
Secondary	toxicity related to the radiotherapy	assess according to the National Cancer Institute-Common Terminology Criteria for Adverse Events 3.0	from the beginning of radiotherapy to the 3 month after the completion of radiotherapy